Progress and challenges in the elimination of hepatitis C among people who inject drugs in Germany: results of a pilot study for a national monitoring system, 10 years after the first data collection

作者：Gyde Steffen, Amrei Krings, Sarah Guttmann, Nadine Lübke, Kristin Meyer-Schlinkmann, Carsten Tiemann, Jörg Timm, Andreas Walker, Ruth Zimmermann, The DRUCK 2.0-study group, Markus Backmund, Hans-Peter Dorsch, Sebastian Bayer, Jörg Ciomber, Miriam G. Gerlich, Astrid Leicht, Martin Kießling, Esther Neumeier, Stine Nielsen, Willehad Rensmann, Dirk Schäffer, Olaf Ostermann, Christiane Stöter, Stefan Wiedemann, Katrin Wimmer · 发表于：Harm Reduction Journal · 年份：2024 · DOI：10.1186/s12954-024-01119-2 · 被引用次数：4 · 研究领域：HIV, Drug Use, Sexual Risk、Hepatitis C virus research、Hepatitis B Virus Studies

BACKGROUND: People who inject drugs (PWID) are at high risk of blood-borne infections, and injection drug use contributes significantly to hepatitis C virus (HCV) transmission. The WHO has therefore set targets of reducing HCV incidence and prevalence among PWID and increasing treatment coverage to eliminate HCV by 2030. The DRUCK study (2011-2014) found high HCV prevalence and low treatment coverage among PWID in Germany. To assess progress in the elimination of HCV among PWID, we conducted a cross-sectional study in two German federal states that piloted a future monitoring. METHODS: PWID aged 16 + who injected drugs (previous 12 months) were recruited in low-threshold drug services and opioid agonist treatment (OAT) practices in Berlin and Bavaria between June 2021 and April 2022. Participants completed a questionnaire on sociodemographics, behaviours and access to care, and were tested for hepatitis B virus (HBV) and HCV, and HIV. Data was analysed regarding HCV prevalence, history of treatment, and risk and prevention behaviours. Results were compared with the DRUCK study. RESULTS: A total of 588 PWID, with a median age of 39 (range: 17-66) years and 68% (399/587) male, were included in the analysis. Of the participants, 61% (353/574) reported receiving OAT and 14% (66/469) recent use of shared needles/syringes during the last 30 days. History of imprisonment was reported by 77% (444/577) and history of homelessness by 75% (428/569) of participants. Among anti-HCV positi...